Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose PHA-794428 in paediatric growth hormone deficiency
2005-005593-79Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2006
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PHA-794428 in growth hormone deficiency (GHD), sponsored by Pfizer. Primary endpoint: Primary: Safety and tolerance of a single subcutaneous injection of PHA-794428. Started Mar 2006; status: terminated.
02
Drugs
PHA-794428
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2005-005593-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005593-79.